Generation Bio
GBIO
GBIO was delisted on the 6th of February, 2026.
88 hedge funds and large institutions have $390M invested in Generation Bio in 2021 Q4 according to their latest regulatory filings, with 22 funds opening new positions, 29 increasing their positions, 23 reducing their positions, and 14 closing their positions.
57% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 14
26% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 23
21% more call options, than puts
Call options by funds: $110K | Put options by funds: $91K
9% more funds holding
Funds holding: 81 → 88 (+7)
1.21% more ownership
Funds ownership: 8.45% → 9.66% (+1.2%)
68% less capital invested
Capital invested by funds: $1.2B → $390M (-$813M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$24.4M |
| 2 |
Millennium Management
New York
|
+$9.4M |
| 3 |
YCM
Yiheng Capital Management
San Francisco,
California
|
+$6.55M |
| 4 |
Two Sigma Investments
New York
|
+$4.24M |
| 5 |
Renaissance Technologies
New York
|
+$4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CG
Carmignac Gestion
Paris,
France
|
-$36.9M |
| 2 |
JP Morgan Chase
New York
|
-$21.8M |
| 3 |
Victory Capital Management
San Antonio,
Texas
|
-$20.5M |
| 4 |
Ensign Peak Advisors
Salt Lake City,
Utah
|
-$10.8M |
| 5 |
Goldman Sachs
New York
|
-$4.85M |
GBIO Hedge Fund Activity: Q4 2021 in Review
88 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Generation Bio (GBIO) for Q4 2021, worth a combined $390M — down 68% from $1.2B a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new GBIO positions and 14 closed out — a net gain of 8 holders — while 29 added to existing stakes and 23 trimmed.
The largest buyer was Bellevue Group, adding an estimated $24.4M. The largest seller was Carmignac Gestion, exiting entirely with an estimated $36.9M sold.
- 88 institutional investors held Generation Bio (GBIO) as of Q4 2021, up from 81 in Q3 2021.
- Funds reported $390M of Generation Bio stock for Q4 2021, down 68% quarter-over-quarter.
- 22 funds opened new Generation Bio positions in Q4 2021 and 14 closed out, a net change of +8 holders.
- The largest Generation Bio buyer in Q4 2021 was Bellevue Group, an estimated $24.4M added.
- The largest Generation Bio seller in Q4 2021 was Carmignac Gestion, an estimated $36.9M sold.
Based on aggregated 13F filings for Q4 2021.